2023 - Research.com Medicine in United Kingdom Leader Award
His primary scientific interests are in Prostate cancer, Internal medicine, Cancer biomarkers, Oncology and Abiraterone acetate. Prostate cancer and Docetaxel are commonly linked in his work. Johann S. de Bono interconnects Endocrinology and Surgery in the investigation of issues within Internal medicine.
His work carried out in the field of Cancer biomarkers brings together such families of science as Cancer research, Prostate, Pharmacology and Circulating tumor cell. His Oncology research incorporates themes from Clinical trial, Neoplasm, Immunology, Prostate-specific antigen and Cohort. His Abiraterone acetate research is multidisciplinary, incorporating perspectives in Androgen and Urology.
Johann S. de Bono mainly investigates Internal medicine, Prostate cancer, Oncology, Cancer biomarkers and Cancer research. His Internal medicine study frequently draws connections between adjacent fields such as Surgery. His work on Prostate cancer is being expanded to include thematically relevant topics such as Docetaxel.
Johann S. de Bono works mostly in the field of Oncology, limiting it down to topics relating to Prednisone and, in certain cases, Placebo, as a part of the same area of interest. His study looks at the relationship between Cancer biomarkers and fields such as Pharmacology, as well as how they intersect with chemical problems. His research integrates issues of Homologous recombination, Prostate and DNA repair in his study of Cancer research.
His primary areas of study are Prostate cancer, Internal medicine, Oncology, Cancer research and Castration resistant. His study in Prostate cancer is interdisciplinary in nature, drawing from both Prostate and Docetaxel. Internal medicine connects with themes related to Gastroenterology in his study.
His biological study spans a wide range of topics, including Cabazitaxel, Abiraterone, Olaparib, Hazard ratio and Biomarker. Johann S. de Bono combines subjects such as Synthetic lethality, DNA damage, Small molecule, Bromodomain and Androgen receptor with his study of Cancer research. As a part of the same scientific family, Johann S. de Bono mostly works in the field of Enzalutamide, focusing on Abiraterone acetate and, on occasion, Prostate-specific antigen, Cohort study and Proportional hazards model.
The scientist’s investigation covers issues in Prostate cancer, Internal medicine, Oncology, Cancer research and Cancer. Johann S. de Bono has researched Prostate cancer in several fields, including Phases of clinical research, DNA repair and PTEN. As part of his studies on Internal medicine, he frequently links adjacent subjects like Gastroenterology.
The study incorporates disciplines such as Olaparib, Hazard ratio, Confidence interval and Docetaxel in addition to Oncology. His Confidence interval study combines topics from a wide range of disciplines, such as Cabozantinib, Mitoxantrone, Abiraterone acetate, Proportional hazards model and Prostate-specific antigen. His work deals with themes such as Synthetic lethality, Prostate, DNA damage and Androgen receptor, which intersect with Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi.
The New England Journal of Medicine (2011)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin.
The New England Journal of Medicine (2012)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt.
The New England Journal of Medicine (2009)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian De Bono;Stephane Oudard;Mustafa Ozguroglu;Steinbjørn Hansen.
The Lancet (2010)
Integrative clinical genomics of advanced prostate cancer
Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz.
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina.
The New England Journal of Medicine (2013)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot.
The New England Journal of Medicine (2014)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono;Howard I. Scher;R. Bruce Montgomery;Christopher Parker.
Clinical Cancer Research (2008)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo;Suzanne Carreira;Shahneen Sandhu;Susana Miranda.
The New England Journal of Medicine (2015)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke.
The New England Journal of Medicine (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: